To direct the Comptroller General of the United States to conduct a study to assess the key regulatory barriers that impede the expansion or siting of new pharmaceutical manufacturing facilities in the United States, and for other purposes.
Citations are generated automatically from bibliographic data
as a convenience and may not be complete or accurate.
Chicago
U.S. Congress. House. Enhancing Domestic Drug Manufacturing Competitiveness Act. H.R. 1405. 119th
Cong., 1st
sess., Introduced in House February 18, 2025. https://www.govinfo.gov/app/details/BILLS-119hr1405ih.
APA
Congress, House of Representatives (2025, February 18). Enhancing Domestic Drug Manufacturing Competitiveness Act (H.R. 1405 (IH)). Retrieved from https://www.govinfo.gov/app/details/BILLS-119hr1405ih.
MLA
United States, Congress, House of Representatives. Enhancing Domestic Drug Manufacturing Competitiveness Act. U.S. Government Publishing Office, https://www.govinfo.gov/app/details/BILLS-119hr1405ih. 119th Congress, H.R. 1405, Introduced in House 18 Feb. 2025.
Bluebook
H.R.1405 - 119th Congress (2025-2026): Enhancing Domestic Drug Manufacturing Competitiveness Act, H.R.1405, 119th Cong. (2025), https://www.govinfo.gov/app/details/BILLS-119hr1405ih.
